EFFICACY AND SAFETY OF SUNITINIB AS FIRST-LINE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SYSTEMATIC REVIEW

被引：0
|
作者：
Huerfano, C. [1 ]
NinoNino, C. P. [1 ]
Davila, F. [1 ]
Reyes, J. M. [2 ]
Diaz, J. A. [3 ]
机构：
[1] Univ Nacl Colombia, Bogota, Colombia
[2] Pfizer SAS, Bogota, Colombia
[3] Univ Nacl Colombia, Bogota, Colombia
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1534
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN201
引用
收藏
页码：A169 / A169
页数：1
相关论文
共 50 条
  • [41] A systematic review and network meta-analysis of first-line treatment options in patients metastatic renal cell carcinoma
    Bin Riaz, Irbaz
    Ryu, Alexander J.
    Yao, Yuan
    Siddiqi, Rabbia
    Mathew, Jessey
    Sipra, Qurat Ul Ain Riaz
    Zahoor, Haris
    Wang, Zhen
    Murad, M. Hassan
    Pagliaro, Lance C.
    Costello, Brian Addis
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [42] First-line Treatment of Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis
    Hahn, Andrew W.
    Klaassen, Zachary
    Agarwal, Neeraj
    Haaland, Benjamin
    Esther, John
    Ye, Xiang Y.
    Wang, Xuechen
    Pal, Sumanta K.
    Wallis, Christopher J. D.
    EUROPEAN UROLOGY ONCOLOGY, 2019, 2 (06): : 708 - 715
  • [43] Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma
    Miyake, Hideaki
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Tamura, Keita
    Suzuki, Takahisa
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsukav, Atsushi
    MEDICAL ONCOLOGY, 2018, 35 (10)
  • [44] Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell carcinoma
    Hideaki Miyake
    Yuto Matsushita
    Hiromitsu Watanabe
    Keita Tamura
    Takahisa Suzuki
    Daisuke Motoyama
    Toshiki Ito
    Takayuki Sugiyama
    Atsushi Otsukav
    Medical Oncology, 2018, 35
  • [45] Optimizing axitinib treatment selection following first-line sunitinib in metastatic renal cell carcinoma.
    Bracarda, Sergio
    Bamias, Aristotelis
    Casper, Jochen
    Negrier, Sylvie
    Sella, Avishay
    Staehler, Michael D.
    Tarazi, Jamal Christo
    Felici, Alessandra
    Rosbrook, Brad
    Jardinaud-Lopez, Monica
    Escudier, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [46] Efficacy and safety of intrapatient dose escalation of sorafenib as first-line treatment for metastatic renal cell carcinoma (mRCC).
    Gore, M. E.
    Jones, R. J.
    Ravaud, A.
    Kuczyk, M.
    Demkow, T.
    Bearz, A.
    Laferriere, N.
    Strauss, U. P.
    Porta, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] The efficacy and safety of sunitinib given on an individualised schedule as first-line therapy for metastatic renal cell carcinoma: A phase 2 clinical trial
    Bjarnason, Georg A.
    Knox, Jennifer J.
    Kollmannsberger, Christian K.
    Soulieres, Denis
    Ernst, D. Scott
    Zalewski, Pawel
    Canil, Christina M.
    Winquist, Eric
    Hotte, Sebastien J.
    North, Scott A.
    Heng, Daniel Yick Chin
    Macfarlane, Robyn Jane
    Venner, Peter M.
    Kapoor, Anil
    Hansen, Aaron R.
    Eigl, Bernhard J.
    Czaykowski, Piotr
    Boyd, Ben
    Wang, Lisa
    Basappa, Naveen S.
    EUROPEAN JOURNAL OF CANCER, 2019, 108 : 69 - 77
  • [48] Optimising first-line treatment for metastatic renal cell carcinoma
    de Velasco, Guillermo
    LANCET, 2020, 395 (10219): : E7 - E7
  • [49] A personalized sunitinib (S) first-line approach in elderly patients with metastatic renal cell carcinoma (mRCC).
    Rocca, Maria Cossu
    Iacovelli, Roberto
    Verri, Elena
    Crescio, Claudia
    Aurilio, Gaetano
    Detti, Serena
    Cullura, Daniela
    Nole, Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [50] Nomogram Predicting Prognosis in Metastatic Patients with Clear Cell Renal Cell Carcinoma Treated by First-Line Sunitinib
    Kammerer-Jacquet, Solene-Florence
    Dugay, Frederic
    Bensalah, Karim
    Brunot, Angelique
    Peyronnet, Benoit
    Mathieu, Romain
    Verhoest, Gregory
    Lefort, Mathilde
    Bayat, Sahar
    Lespagnol, Alexandra
    Mosser, Jean
    Edeline, Julien
    Laguerre, Brigitte
    Dupuis, Frantz
    Yacoub, Mokrane
    Ravaud, Alain
    Bernhard, Jean-Christophe
    Belaud-Rotureau, Marc-Antoine
    Rioux-Leclercq, Nathalie
    LABORATORY INVESTIGATION, 2017, 97 : 234A - 234A
12345